Literature DB >> 16822348

PARK8 LRRK2 parkinsonism.

Kristoffer Haugarvoll, Zbigniew K Wszolek.   

Abstract

Parkinson's disease (PD) is the most common form of parkinsonism, affecting nearly 2% of people older than 65 years of age. Symptomatic treatment has been available for decades, but to date there is no treatment retarding disease progression. Over the past decade several genes causing parkinsonism have been identified in families with a mendelian pattern of inheritance. The most recent is the leucine-rich repeat kinase 2 (LRRK2) gene. Pathogenic mutations in the LRRK2 gene cause a significant proportion of clinically typical, late-onset PD. This review summarizes the current knowledge on the contribution of LRRK2 mutations in understanding parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822348     DOI: 10.1007/s11910-006-0020-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  59 in total

1.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Authors:  Alexander Zimprich; Bertram Müller-Myhsok; Matthew Farrer; Petra Leitner; Manu Sharma; Mary Hulihan; Paul Lockhart; Audrey Strongosky; Jennifer Kachergus; Donald B Calne; Jon Stoessl; Ryan J Uitti; Ronald F Pfeiffer; Claudia Trenkwalder; Nikolaus Homann; Erwin Ott; Karoline Wenzel; Friedrich Asmus; John Hardy; Zbigniew Wszolek; Thomas Gasser
Journal:  Am J Hum Genet       Date:  2003-12-19       Impact factor: 11.025

2.  LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.

Authors:  Jon Infante; Eloy Rodríguez; Onofre Combarros; Ignacio Mateo; Ana Fontalba; Julio Pascual; Agustín Oterino; José Miguel Polo; Carlos Leno; José Berciano
Journal:  Neurosci Lett       Date:  2005-11-18       Impact factor: 3.046

3.  Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.

Authors:  Denise M Kay; Patricia Kramer; Don Higgins; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

4.  Lrrk2 and Lewy body disease.

Authors:  Owen A Ross; Mathias Toft; Andrew J Whittle; Joseph L Johnson; Spiridon Papapetropoulos; Deborah C Mash; Irene Litvan; Mark F Gordon; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

5.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 6.  A systematic review of prevalence studies of dementia in Parkinson's disease.

Authors:  Dag Aarsland; Julia Zaccai; Carol Brayne
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

7.  Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease.

Authors:  Lisa Skipper; Yi Li; Carine Bonnard; Ratnagopal Pavanni; Yuen Yih; Eva Chua; Wing-Kin Sung; Louis Tan; Meng-Cheong Wong; Eng-King Tan; Jianjun Liu
Journal:  Hum Mol Genet       Date:  2005-11-03       Impact factor: 6.150

8.  Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium.

Authors:  C Paisán-Ruíz; E W Evans; S Jain; G Xiromerisiou; J R Gibbs; J Eerola; V Gourbali; O Hellström; J Duckworth; A Papadimitriou; P J Tienari; G M Hadjigeorgiou; A B Singleton
Journal:  J Med Genet       Date:  2006-02       Impact factor: 6.318

9.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

10.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Authors:  Alessio Di Fonzo; Cristina Tassorelli; Michele De Mari; Hsin F Chien; Joaquim Ferreira; Christan F Rohé; Giulio Riboldazzi; Angelo Antonini; Gianni Albani; Alessandro Mauro; Roberto Marconi; Giovanni Abbruzzese; Leonardo Lopiano; Emiliana Fincati; Marco Guidi; Paolo Marini; Fabrizio Stocchi; Marco Onofrj; Vincenzo Toni; Michele Tinazzi; Giovanni Fabbrini; Paolo Lamberti; Nicola Vanacore; Giuseppe Meco; Petra Leitner; Ryan J Uitti; Zbigniew K Wszolek; Thomas Gasser; Erik J Simons; Guido J Breedveld; Stefano Goldwurm; Gianni Pezzoli; Cristina Sampaio; Egberto Barbosa; Emilia Martignoni; Ben A Oostra; Vincenzo Bonifati
Journal:  Eur J Hum Genet       Date:  2006-03       Impact factor: 4.246

View more
  6 in total

1.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

2.  Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway.

Authors:  Anthony K F Liou; Rehana K Leak; Lihua Li; Michael J Zigmond
Journal:  Neurobiol Dis       Date:  2008-07-08       Impact factor: 5.996

3.  GTPase activity plays a key role in the pathobiology of LRRK2.

Authors:  Yulan Xiong; Candice E Coombes; Austin Kilaru; Xiaojie Li; Aaron D Gitler; William J Bowers; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  PLoS Genet       Date:  2010-04-08       Impact factor: 5.917

4.  Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

Authors:  R Nandhagopal; E Mak; M Schulzer; J McKenzie; S McCormick; V Sossi; T J Ruth; A Strongosky; M J Farrer; Z K Wszolek; A J Stoessl
Journal:  Neurology       Date:  2008-11-25       Impact factor: 9.910

5.  Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

Authors:  David Ramonet; João Paulo L Daher; Brian M Lin; Klodjan Stafa; Jaekwang Kim; Rebecca Banerjee; Marie Westerlund; Olga Pletnikova; Liliane Glauser; Lichuan Yang; Ying Liu; Deborah A Swing; M Flint Beal; Juan C Troncoso; J Michael McCaffery; Nancy A Jenkins; Neal G Copeland; Dagmar Galter; Bobby Thomas; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

Review 6.  From the tyrosine hydroxylase hypothesis of Parkinson's disease to modern strategies: a short historical overview.

Authors:  Wolf-Dieter Rausch; Feixue Wang; Khaled Radad
Journal:  J Neural Transm (Vienna)       Date:  2022-04-23       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.